Plus Therapeutics Inc

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Plus Therapeutics advances trials, secures funding, and expands diagnostics

Plus Therapeutics demonstrates strong financial and operational progress with successful funding, grants, and trial advancements.
Strategic additions to the management team and diagnostic capabilities enhance the company's expertise and market positioning.
Challenges in financial management, regulatory processes, and dosing strategies require careful navigation for sustained growth and success.
Opportunities lie in FDA feedback, commercial launches, collaborations, and positive trial outcomes for future growth and market impact.

Plus Therapeutics Inc (PSTV) reports clinical progress amidst financial challenges

Plus Therapeutics Inc (PSTV) made significant clinical advancements in Q2 2024, while facing financial challenges. The company's strengths include positive trial results and supportive conference data, with opportunities for growth through expanded capabilities and funding access.

Plus Therapeutics progresses in leptomeningeal metastases program with strong financial backing

Plus Therapeutics is advancing promising treatments for leptomeningeal metastases with encouraging clinical data and FDA support.
Financially, the company is well-positioned with a solid cash balance, expected grant revenue, and access to diverse funding sources.
Strategic focus on upcoming events, milestones, and product launches underscores the company's commitment to innovation and growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dr. Robert Lenk and Mr. Howard Clowes Dr. Robert Lenk and Mr. Howard Clowes

Plus Therapeutics Welcomes Two New Directors

AUSTIN, Texas, Feb.  06, 2020  (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), today announced that Andrew J. Sims has been appointed as the company’s Chief Financial Officer, effective February 5, 2020.

Plus Therapeutics Appoints Chief Financial Officer

AUSTIN, Texas, Feb.  06, 2020  (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), today announced that Greg B. Petersen has joined the Company’s Board of Directors to serve as an independent director, effective February 14, 2020.  Greg will serve on the Audit and Compensation Committees.  In addition, on January 31, 2020, Gregg Lapointe, submitted his resignation from the board of directors.

Plus Therapeutics Announces Changes to its Board of Directors

AUSTIN, Texas, Jan.  06, 2020  (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”) today issued the following Letter to Shareholders from Dr. Marc Hedrick, President and Chief Executive Officer.

Plus Therapeutics Shareholder Update: Transition Achieved in 2019; Poised for Expansion in 2020

AUSTIN, Texas, Jan.  02, 2020  (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), today announced that Dr. An van Es-Johansson has joined the Company’s Board of Directors to serve as an independent director, effective January 1, 2020.

Plus Therapeutics Appoints Dr. An van Es-Johansson to Board of Directors

Plus Therapeutics, Inc. (PSTV) CEO Dr.

AUSTIN, Texas, Oct.  15, 2019  (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”) today announced that it received a $4.6 million payment from the U.S. Department of Health and Human Services / Office of the Assistant Secretary for Preparedness and Response / Biomedical Advanced Research and Development Authority (“BARDA”) to reimburse the Company for work performed during fiscal years 2012 through 2019, based on retrospective changes in indirect cost rates under Contract HHSO100201200008C dated September 27, 2012, as amended, by and between the Company and BARDA.

Plus Therapeutics Receives $4.6MM Reimbursement Payment

AUSTIN, Texas, Sept.  26, 2019  (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 3,000,000 units, each unit consisting of one share of common stock (or a common stock equivalent) and one Series U Warrant to purchase one share of common stock at a public offering price of $5.00 per unit.  The shares of common stock (or common stock equivalents) and warrants comprising the units were immediately separable and were issued separately, but were purchased together.  The Series U Warrants have an exercise price of $5.00 per share, are immediately exercisable and will expire 5 years from the date of issuance.  In addition, the underwriter has exercised its option to purchase additional Series U Warrants to purchase up to 450,000 shares of common stock.  The Company has also granted the underwriter a 45-day option to purchase up to an additional 450,000 shares of common stock.

Plus Therapeutics, Inc. Announces Closing of $15 Million Underwritten Public Offering

AUSTIN, Texas, Sept.  23, 2019  (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced the pricing of an underwritten public offering (the “Offering”) of 3,000,000 units, each unit consisting of one share of common stock (or a common stock equivalent) and one Series U Warrant to purchase one share of common stock at a public offering price of $5.00 per unit. The shares of common stock (or common stock equivalents) and warrants comprising the units are immediately separable and will be issued separately, but will be purchased together. The Series U Warrants have an exercise price of $5.00 per share, are immediately exercisable and will expire five years from the date of issuance. The Company has granted the underwriter a 45-day option to purchase up to an additional 450,000 shares of common stock and/or Series U Warrants to purchase up to 450,000 shares of common stock.

Plus Therapeutics, Inc. Announces Pricing Of $15 Million Underwritten Public Offering

AUSTIN, Texas, Sept.  23, 2019  (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”) today announced that it received notice from the U.S. Department of Health and Human Services / Office of the Assistant Secretary for Preparedness and Response / Biomedical Advanced Research and Development Authority (“BARDA”) that, based on retrospective changes in indirect cost rates under Contract HHSO100201200008C dated September 27, 2012, as amended, BARDA has agreed to pay the Company approximately $4.6 million to reimburse the Company for work performed during fiscal years 2012 through 2019.  The Company expects to receive such payment from BARDA in October 2019.

Plus Therapeutics to Receive $4.6MM Reimbursement Payment

Plus Therapeutics Inc (NASDAQ: PSTV) is the latest and one of the most extreme recent examples of the powerful combination of low float and heavy trading volume.

Heavy Volume Drives Low-Float Stock Plus Therapeutics Up 200%

News for Plus Therapeutics Inc Stock (PSTV)